What is the max dose of ropivacaine?

The maximum dose of ropivacaine is 3 mg/kg without epinephrine and 3.5 mg/kg with epinephrine for adults, with an absolute maximum of 250 mg regardless of patient weight or epinephrine use. For children and adolescents, the maximum is capped at 3 mg/kg even with epinephrine.

Is ropivacaine safer than bupivacaine?

Ropivacaine has a safer cardiovascular profile than bupivacaine. It has a cardiotoxicity rating of 2 out of 5 compared to bupivacaine's higher cardiotoxicity. Ropivacaine causes less myocardial depression and is less likely to produce refractory ventricular arrhythmias. This improved CV safety margin is a key reason ropivacaine is often preferred for high-volume regional techniques.

What is the ropivacaine pediatric dose?

Ropivacaine pediatric dosing uses age-tiered scaling: Neonates (<1 month) receive 50% of the adult dose, Young Infants (1-6 months) receive 70%, Older Infants (6-12 months) receive 75%, and Children (1-7 years) and Adolescents (8+ years) receive 100% of the weight-based dose. Critically, children and adolescents are capped at 3 mg/kg with epinephrine — they do NOT receive the adult 3.5 mg/kg with-epi dose. The absolute maximum remains 250 mg. Infants under 3 months have a 36-hour continuous infusion limit.

Ropivacaine Dosing Guide

Maximum Doses, Pediatric Tiers & Cardiovascular Safety Profile

Long-acting amide local anesthetic · CYP1A2 metabolism · Cardiotoxicity 2/5

CLINICAL DECISION SUPPORT TOOL. This page is a reference for licensed healthcare professionals. It does not replace clinical judgment. Always verify doses against current guidelines and institutional protocols before administration.

Adult Dosing

Parameter	Without Epinephrine	With Epinephrine
Max dose (mg/kg)	3 mg/kg	3.5 mg/kg
Absolute max	250 mg	250 mg
Onset	10-20 minutes (route dependent)
Duration	4-8 hours	5-10 hours

The absolute maximum of 250 mg applies regardless of patient weight. For an 80 kg adult without epinephrine: 3 mg/kg x 80 kg = 240 mg (below cap). For a 100 kg adult: 3 mg/kg x 100 kg = 300 mg, but capped at 250 mg.

Pediatric Dosing

Ropivacaine pediatric dosing uses age-tiered dose fractions applied to the adult weight-based maximum. The absolute max remains 250 mg across all tiers.

Age Tier	Age Range	Dose Fraction	Without Epi	With Epi
Neonate	< 1 month	50%	1.5 mg/kg	1.5 mg/kg
Young Infant	1 – < 6 months	70%	2.1 mg/kg	2.1 mg/kg
Older Infant	6 – < 12 months	75%	2.25 mg/kg	2.25 mg/kg
Child	1 – 7 years	100%	3 mg/kg	3 mg/kg
Adolescent	8+ years	100%	3 mg/kg	3 mg/kg

PEDIATRIC EPINEPHRINE CAP. Children and adolescents are capped at 3 mg/kg with epinephrine. They do NOT receive the adult 3.5 mg/kg with-epi dose. This is a deliberate safety constraint in the pediatric population.

For infants in the lower tiers, the dose fraction reduces both the no-epi and with-epi maximums proportionally. Example: A 4 kg neonate (50% tier) has a max of 1.5 mg/kg x 4 kg = 6 mg without epinephrine.

Cardiovascular Safety Profile

Cardiotoxicity Rating: 2 out of 5. Ropivacaine has a significantly safer cardiovascular profile than bupivacaine. It produces less myocardial depression and is less likely to cause refractory ventricular arrhythmias, making it a preferred choice for high-volume regional techniques.

Property	Ropivacaine	Bupivacaine
Cardiotoxicity rating	2/5	Higher (more cardiotoxic)
Myocardial depression	Less	More
Refractory arrhythmia risk	Lower	Higher
CV:CNS toxicity ratio	More favorable	Less favorable
Stereoisomer	S-enantiomer (pure)	Racemic mixture

Ropivacaine's improved CV safety comes from its S-enantiomer formulation and lower lipid solubility compared to bupivacaine. The wider margin between CNS and cardiovascular toxicity thresholds provides a larger clinical safety window. This makes it particularly suitable for epidural infusions, large-volume peripheral nerve blocks, and wound infiltration where total dose requirements are higher.

Infusion Limits

Patient Population	Infusion Limit
Adults	Per institutional protocol
Children ≥ 3 months	Per institutional protocol
Infants < 3 months	36-hour maximum continuous infusion

NEONATAL INFUSION LIMIT. Infants under 3 months must not receive continuous ropivacaine infusions exceeding 36 hours. Immature hepatic metabolism (reduced CYP1A2 activity) leads to drug accumulation and increased toxicity risk in this population.

Pharmacokinetics

Parameter	Value
Classification	Long-acting amide local anesthetic
Half-life	1.8 hours
Metabolism	Hepatic via CYP1A2
Protein binding	~94%
pKa	8.1
Stereochemistry	Pure S-enantiomer

CYP1A2 is the primary metabolic pathway. CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, amiodarone) may increase plasma levels and toxicity risk. Neonates have significantly reduced CYP1A2 activity, which is the basis for both the age-tiered dose reductions and the 36-hour infusion limit in infants under 3 months.

Clinical Notes

Concentration selection: 0.2% for analgesia/infusions, 0.5% for surgical anesthesia, 0.75% for epidural cesarean delivery and major nerve blocks.
Motor-sensory dissociation: At lower concentrations (0.2%), ropivacaine produces more sensory-selective blockade with less motor block than bupivacaine, advantageous for labor epidurals and postoperative infusions.
Epinephrine benefit: The with-epi dose increase is modest (3 to 3.5 mg/kg in adults) compared to some other local anesthetics, because ropivacaine already has intrinsic vasoconstrictive properties.
Adolescent epi cap: Despite receiving 100% of the weight-based dose, adolescents are capped at 3 mg/kg with epinephrine (not the adult 3.5 mg/kg). This is a deliberate pediatric safety constraint.
CYP1A2 drug interactions: Check for concurrent fluvoxamine, ciprofloxacin, or other CYP1A2 inhibitors that could impair clearance.
LAST preparedness: Have 20% lipid emulsion (Intralipid) immediately available. See the LAST Protocol for dosing and treatment steps.

Calculate Safe Ropivacaine Doses with MaxLocal

Weight-based dosing with age-tiered pediatric scaling, fractional toxicity tracking across multiple agents, and instant LAST protocol access — all offline.

Get MaxLocal on Google Play

Learn more at max-local.app

Related Dosing Guides

References

Rosenberg PH, Veering BT, Urmey WF. Maximum recommended doses of local anesthetics: a multifactorial concept. Reg Anesth Pain Med. 2004;29(6):564-575.
Knudsen K, Beckman Suurkula M, Blomberg S, et al. Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth. 1997;78(5):507-514.
Scott DB, Lee A, Fagan D, et al. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg. 1989;69(5):563-569.
Neal JM, Barrington MJ, Fettiplace MR, et al. The Third ASRA Practice Advisory on Local Anesthetic Systemic Toxicity. Reg Anesth Pain Med. 2020;45(4):247-253.
Suresh S, Ecoffey C, Bosenberg A, et al. The European Society of Regional Anaesthesia and Pain Therapy/American Society of Regional Anesthesia and Pain Medicine Recommendations on Local Anesthetics and Adjuvants Dosage in Pediatric Regional Anesthesia. Reg Anesth Pain Med. 2018;43(2):211-216.

Clinical Decision Support Tool. This page is intended as a reference aid for licensed healthcare professionals only. It does not replace clinical judgment. Always verify information against current guidelines and institutional protocols before clinical use.